Novo Nordisk (NVO) said that the Committee for Medicinal Products for Human Use or CHMP under the European Medicines Agency or EMA has adopted a positive opinion, recommending marketing authorisation for Ozempic or semaglutide for the treatment of adults with type 2 diabetes mellitus.
The CHMP recommends Ozempic, the intended brand name for once-weekly semaglutide, to be indicated as monotherapy when metformin no longer provides sufficient treatment or is contraindicated and as an addition to other medicinal products for the treatment of diabetes. The indication also refers to specific sections of the label for study results with respect to combination with other diabetes medications, effects on glycaemic control, cardiovascular events and the populations studied.
Novo Nordisk expects to receive final marketing authorisation from the EuropeanCommission in the first quarter of 2018.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.